Wall Street Zen Upgrades TuHURA Biosciences (NASDAQ:HURA) to “Hold”

TuHURA Biosciences (NASDAQ:HURA) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other equities analysts also recently issued research reports about the company. Maxim Group cut their target price on TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, January 22nd. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of TuHURA Biosciences in a research report on Tuesday, February 3rd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

TuHURA Biosciences Price Performance

Shares of HURA stock opened at $1.90 on Friday. The company has a market cap of $115.37 million, a PE ratio of -3.80 and a beta of -0.30. TuHURA Biosciences has a 1 year low of $0.41 and a 1 year high of $4.44. The stock’s 50 day simple moving average is $1.06 and its two-hundred day simple moving average is $1.71.

Institutional Investors Weigh In On TuHURA Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC bought a new stake in shares of TuHURA Biosciences during the 3rd quarter worth approximately $26,000. JPMorgan Chase & Co. bought a new position in TuHURA Biosciences in the 2nd quarter valued at $27,000. Intech Investment Management LLC purchased a new stake in TuHURA Biosciences in the second quarter worth $29,000. Invesco Ltd. bought a new stake in shares of TuHURA Biosciences during the second quarter worth $30,000. Finally, State Street Corp lifted its position in shares of TuHURA Biosciences by 4.9% during the fourth quarter. State Street Corp now owns 289,133 shares of the company’s stock worth $219,000 after purchasing an additional 13,594 shares during the last quarter. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.